Avian influenza vaccines: what's all the flap?

Lancet

Volumn 367, Issue 9523, 2006, Pages 1636-1638

  Sambhara, Suryaprakash ^a   Poland, Gregory A ^b  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b Mayo Vaccine Research Group   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADJUVANT; ALUMINUM HYDROXIDE; ANTIBODY; ANTIGEN; HEMAGGLUTININ; INFLUENZA VACCINE; NEUTRALIZING ANTIBODY; SIALIDASE; VIRUS VECTOR;

ARTICLE; AVIAN INFLUENZA; CLINICAL TRIAL; DRUG FORMULATION; DRUG TOLERABILITY; HUMAN; IMMUNOGENICITY; PASSIVE IMMUNIZATION; PRIORITY JOURNAL; SEROCONVERSION; T LYMPHOCYTE; UNSPECIFIED SIDE EFFECT; VIRAL GENE DELIVERY SYSTEM;

EID: 33646550529     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(06)68657-1     Document Type: Note

References (12)

1. WHO. Cumulative number of confirmed human cases of avian influenza A/(H5N1) reported to WHO. http://www.who.int/csr/disease/avian_influenza/country/cases_table_2006_05_05/en/index.html (accessed May 6, 2006)
2. Ungchusak K., Auewarakul P., Dowell S., et al. Probable person-to-person transmission of avian influenza A (H5N1). N Engl J Med 352 (2005) 333-340
3. Nicholson K., Colegate A., Podda A., et al. Safety and antigenicity of non-adjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a randomised trial of two potential vaccines against H5N1 influenza. Lancet 357 (2001) 1937-1943
4. Treanor J., Wilkinson B., Masseoud F., et al. Safety and immunogenicity of a recombinant hemagglutinin vaccine for H5 influenza in humans. Vaccine 19 (2001) 1732-1737
5. Treanor J., Campbell J., Zangwill K., Rowe T., and Wolff M. Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine. N Engl J Med 354 (2006) 1343-1351
6. Poland G. Vaccines against avian influenza-a race against time. N Engl J Med 354 (2006) 1411-1413
7. Bresson J.-L., Perronne C., Launay O., et al. Safety and immunogenicity of an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine: phase I randomised trial. Lancet 367 (2006) 1657-1664
8. Hoelscher M., Garg S., Bangari D., et al. Development of adenoviral-vector-based pandemic influenza vaccine against antigenically distinct human H5N1 strains in mice. Lancet 367 (2006) 475-481
9. Karaca K., Swayne D., Grosenbaugh D., et al. Immunogenicity of fowlpox virus expressing the avian influenza virus H5 gene (TROVAC AIV-H5) in cats. Clin Diagn Lab Immunol 12 (2005) 1340-1342
10. Rimmelzwaan G., Claas E., van Amerongen G., de Jong J., and Osterhaus A. ISCOM vaccine induced protection against a lethal challenge with a human H5N1 influenza virus. Vaccine 17 (1999) 1355-1358
11. Sambhara S., Kurichh A., Miranda R., et al. Heterosubtypic immunity against human influenza A viruses, including recently emerged avian H5 and H9 viruses, induced by FLU-ISCOM vaccine in mice requires both cytotoxic T-lymphocyte and macrophage function. Cell Immunol 211 (2001) 143-153
12. Food and Drug Administration Center for Biologics Evaluation and Research. Guidance for industry: clinical data needed to support the licensure of pandemic influenza vaccines (March, 2006). http://www.fda.gov/cber/gdlns/panfluvac.pdf (accessed May 5, 2006)